KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.66

-1.3%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$87.15M
EPS-2.8500
P/E Ratio-1.64
Earnings Date08/12/2026

klrs

Depreciation and Amortization

Last Annual Value

13.00K

3-Year CAGR

%

5-Year CAGR

-29%

10-Year CAGR

-16%

KT

Kalaris Therapeutics Inc Competitors Analysis of Depreciation and Amortization

KLRS · NASDAQ
CompanyDepreciation and Amortization
CAGR 3Y
CAGR 5Y
CAGR 10Y
13.00K
N/A-59.0%N/A 
273.00K
-44.5%2.9%17.1%
717.00K
-31.9%23.7%N/A
3.69M
-3.0%21.7%N/A
16.25K
10.5%N/AN/A
5.32M
8.1%68.9%N/A
3.65M
-13.5%-4.7%8.6%
706.00K
-5.5%69.1%N/A
1.13M
58.0%10.8%N/A
21.00K
-33.1%-20.9%N/A
121.00K
-14.9%9.5%40.6%
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.66, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.66